link 세부 정보
정보 바로가기 : Blincyto expands indication to Ph-negative BCP ALL consolidation therapy
Blincyto expands indication to Ph-negative BCP ALL consolidation therapy[카테고리 설정이 아직되어 있지 않습니다.]
Besides, the three-year recurrence-free survival (RFS) rate was 80 percent in the Blincyto plus chemotherapy arm vs. 64 percent in the chemotherapy-alone arm, giving the Blincyto plus...